🟢 Pacific Biosciences is trading 12.57% up — no clear September 30 catalyst identified

Pacific Biosciences is trading at $2.06, up 12.57%, with no clear September 30 catalyst identified.

• A contemporaneous market report also described the move as lacking a session-specific catalyst.
• The recent five-year VA contract awarded to Sampled supports research using PacBio Revio systems. It was announced earlier, and reporting tied it to prior-session gains—not clearly to this move.
• The Nasdaq is up 0.67%, but there is not enough evidence to attribute Pacific Biosciences’ larger rise to the broader market.